GlassScriptPhysician profile
Lindsey Mears
NPI 1235677113
$3,555.24
in general payments reported to CMS, 2019-2025
27 companies · $864 in 2025
The $864 reported for 2025 was more than what 84% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $382 · 2022: $513 · 2023: $921 · 2024: $876 · 2025: $864.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,660.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,660.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $700.44 | 2021-2025 | General - Pain Management, General - Therapies, Wavewriter Alpha Prime 16 |
| Abbott Laboratories | $531.18 | 2021-2025 | Proclaim, Eterna |
| Abbvie INC. | $359.93 | 2023-2024 | |
| Forte Bio-Pharma LLC | $256.72 | 2024 | Prolate, Nalocet |
| Scilex Pharmaceuticals INC. | $224.54 | 2021-2024 | Ztlido |
| Ibsa Pharma INC. | $218.17 | 2021-2025 | Tirosint, Licart, Licart |
| Medtronic, INC. | $177.78 | 2022-2025 | Inceptiv, Intellis Adaptivestim |
| Collegium Pharmaceutical, INC. | $130.60 | 2023-2025 | Xtampza, Belbuca |
| Revance Therapeutics, INC. | $127.51 | 2024-2025 | Daxxify |
| Relievant Medsystems, INC. | $106.67 | 2022 | |
| Nevro Corp. | $101.26 | 2022-2024 | Senza |
| Idorsia Pharmaceuticals US INC | $100.97 | 2022-2024 | Quviviq |
| Azurity Pharmaceuticals, INC. | $83.65 | 2023-2025 | Horizant, Horizant |
| Bioventus LLC | $60.28 | 2022-2025 | Durolane, Durolane |
| Vertex Pharmaceuticals Incorporated | $55.16 | 2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hikma Pharmaceuticals USA | $48.91 | 2021-2022 | |
| Averitas Pharma INC. | $47.19 | 2023-2025 | Qutenza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.90 | 2025 | Relistor |
| Curonix LLC | $36.74 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pfizer INC. | $26.02 | 2021 | |
| Biotronik Nro, INC. | $24.74 | 2025 | Prospera |
| Masimo Corporation | $24.43 | 2023 | Patient Safetynet System |
| Stimwave Technologies Incorporated | $15.98 | 2021 | |
| Protega Pharmaceutials INC | $15.91 | 2023 | Roxybond |
| Horizon Therapeutics Plc | $15.08 | 2022 | |
| Biodelivery Sciences International, INC. | $12.61 | 2021 | |
| Arbor Pharmaceuticals, INC. | $11.87 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsey Mears listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.